Q4 2016 13F Holders as of 31 Dec 2016
-
Type / Class
-
Debt / NOTE 3.250% 7/0
-
Market price (% of par)
-
89.62%
-
Total 13F principal
-
$405,912,000
-
Principal change
-
-$3,538,000
-
Total reported market value
-
$363,347,000
-
Number of holders
-
43
-
Value change
-
-$11,353,945
-
Number of buys
-
22
-
Number of sells
-
23
Institutional Holders of INTERCEPT PHARMACEUTICALS IN - NOTE 3.250% 7/0 as of Q4 2016
As of 31 Dec 2016,
INTERCEPT PHARMACEUTICALS IN - NOTE 3.250% 7/0 was held by
43 institutional
bondholders
reporting positions in Form 13F filings.
These institutions reported holding
$405,912,000
in principal (par value) of the bond.
The largest 10 bondholders included
HIGHFIELDS CAPITAL MANAGEMENT LP, CITADEL ADVISORS LLC, WOLVERINE ASSET MANAGEMENT LLC, Capital World Investors, MACKAY SHIELDS LLC, Linden Advisors LP, UBS Group AG, ROYAL BANK OF CANADA, UBS ASSET MANAGEMENT AMERICAS INC, and Polar Capital LLP.
This page lists
43
institutional bondholders reporting positions
for the Q4 2016 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price (% of par)
|
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.